Immunovant Inc. (IMVT)
NASDAQ: IMVT
· Real-Time Price · USD
14.85
-0.04 (-0.27%)
At close: May 30, 2025, 3:59 PM
14.85
0.01%
After-hours: May 30, 2025, 04:21 PM EDT
-0.27% (1D)
| Bid | 13.99 |
| Market Cap | 2.52B |
| Revenue (ttm) | 1.5M |
| Net Income (ttm) | -382.71M |
| EPS (ttm) | -2.73 |
| PE Ratio (ttm) | -5.44 |
| Forward PE | -4.71 |
| Analyst | Buy |
| Ask | 15.49 |
| Volume | 1,102,292 |
| Avg. Volume (20D) | 1,734,637 |
| Open | 14.77 |
| Previous Close | 14.89 |
| Day's Range | 14.38 - 15.03 |
| 52-Week Range | 12.72 - 34.47 |
| Beta | 0.75 |
About IMVT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMVT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMVT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 day ago
+5.6%
Immunovant shares are trading higher following a Q...
Unlock content with
Pro Subscription
2 months ago
+4.29%
Immunovant shares are trading higher. B of A Securities and Guggenheim reiterated Buy ratings on the stock.
2 months ago · seekingalpha.com
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going ForwardImmunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoc...
